Glucagon-like peptide-3 (GLP-3) is making waves in the medical field, particularly regarding its role in metabolism and weight management.
It’s equally important for both patients and healthcare providers to be aware of its core principles and potential advantages.
In this blog post, we’ll shed light on the three cornerstones of GLP-3, what benefits it has seen in clinical practice, and more…
Let’s break them down in detail…
The 3 Integral Pillars of GLP-3
GLP-3s operate by binding to and stimulating three distinct receptors in the body, providing a comprehensive metabolic response:
GLP-1 (Glucagon-Like Peptide-1): Promotes satiety (fullness) by signaling to the brain, delays stomach emptying, and naturally stimulates insulin production when blood sugar is high.
GIP (Glucose-Dependent Insulinotropic Polypeptide): Works synergistically with GLP-1 to enhance insulin secretion and further regulate hunger signals in the brain.
Glucagon: Signals to the liver and fat cells to break down stored fat for fuel (thermogenesis), significantly revving up the body’s metabolism and enhancing energy expenditure.
Proven Clinical Benefits
Due to this three-pronged hormonal effect, the GLP-3 drugs continue to deliver very promising results in current clinical trials, including the ongoing study that Eli Lilly conducted with retatrutide:
Significant Weight Loss: Trial participants experienced average weight losses of up to \(25\%\) of their body weight over roughly 48 weeks.
Blood Sugar Control: Patients with Type 2 diabetes saw a decrease in A1C levels (a measure of average blood sugar) by 1.7% to 2.0%.
Metabolic Flexibility: By targeting glucagon alongside the other hormones, the body reduces ectopic fat deposition, lowers triglycerides, and minimizes adipose tissue inflammation.
What You Should Know
Safety & Approval: GLP-3 drugs, such as retatrutide, are undergoing high-level (Phase 3) clinical trials and have not yet been approved for public use or made commercially available for prescription.
Side Effects: As with other incretin-based therapies, anticipated side effects primarily involve the gastrointestinal tract and may include nausea, constipation, or diarrhea.
Availability Risks: While unapproved versions of these compounds have cropped up in the compounding and gray markets. Medical professionals strongly advise against sourcing or using investigational drugs outside of a supervised, clinical trial environment.
Future Directions
GLP-3 is now known to play many roles and has become of interest to researchers developing therapeutics based on this hormone.
Future studies will likely focus on enhancing the efficacy and safety profiles of GLP-3 analogs, including exploring combination therapies that synergize with other glucose-lowering agents.
Furthermore, researchers are exploring the potential use of GLP-3 in modern medicines for cardiovascular health; recent studies indicate that this hormone could also offer protection to heart function.
The study not only underscores GLP-3’s versatility but also holds promise for new therapeutic approaches that could revolutionize the treatment of metabolic disorders.
Wrapping It Up
GLP-3 is emerging as a cornerstone of metabolic health, supported by robust clinical evidence and ongoing research.
Its three pillars—mechanism of action, clinical applications, and future directions—demonstrate the hormone’s potential in addressing some of the most pressing health challenges today.
As we move forward, increasing awareness and understanding of GLP-3 will be essential for achieving better health outcomes.
By embracing knowledge about GLP-3, researchers and healthcare providers can work together to leverage this powerful hormone to improve metabolic health.
